Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (Nasdaq: CLDI) is a clinical-stage biotechnology company focused on developing oncolytic virus-based cancer therapies, including stem-cell-based platforms designed to amplify and deliver tumor-targeting viruses systemically. The company entered the public markets through a de-SPAC merger with First Light Acquisition Group, a blank-check company that completed its IPO in 2021, placing Calidi in the healthcare and biopharmaceutical sector. The November 2021 10-Q filing, bearing accession number 0001193125-21-328251, reflects an early reporting period during the company's pre-merger phase, when it was operating as a private clinical-stage entity ahead of its eventual Nasdaq listing under the CLDI ticker. For full filing history, current status, sponsor details, and deal timeline data on CLDI and hundreds of other SPAC transactions, sign up for complete access at SpacDesk.